ArticleLeukemia2023

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.

Uwe Platzbecker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.